This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, A. Articles by Sun, E. Search for Related Content PubMed PubMed Citation Articles by Hsu, A. Articles by Sun, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 350-359, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.350-359.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064

Received 7 February 2002/ Returned for modification 19 June 2002/ Accepted 3 October 2002

The steady-state pharmacokinetics and pharmacodynamics of two oral doses of lopinavir-ritonavir (lopinavir/r; 400/100 and 533/133 mg) twice daily (BID) when dosed in combination with efavirenz, plus two nucleoside reverse transcriptase inhibitors, were assessed in a phase II, open-label, randomized, parallel arm study in 57 multiple protease inhibitor-experienced but non-nucleoside reverse transcriptase inhibitor-naive human immunodeficiency virus (HIV)-infected subjects. All subjects began dosing of lopinavir/r at 400/100 mg BID; subjects in one arm increased the lopinavir/r dose to 533/133 mg BID on day 14. When codosed with efavirenz, the lopinavir/r 400/100 mg BID regimen resulted in lower lopinavir concentrations in plasma, particularly C_min, than were observed in previous studies of lopinavir/r administered without efavirenz. Increasing the lopinavir/r dose to 533/133 mg increased the lopinavir area under the concentration-time curve over a 12-h dosing interval (AUC₁₂), C_predose, and C_min by 46, 70, and 141%, respectively. The increase in lopinavir C_max (33%,) did not reach statistical significance. Ritonavir AUC₁₂, C_max, C_predose, and C_min values were increased 46 to 63%. The lopinavir predose concentrations achieved with the 533/133-mg BID dose were similar to those observed with lopinavir/r 400/100 mg BID in the absence of efavirenz. Results from univariate logistic regression analyses identified lopinavir and efavirenz inhibitory quotient (IQ) parameters, as well as the baseline lopinavir phenotypic susceptibility, as predictors of antiviral response (HIV RNA < 400 copies/ml at week 24); however, no lopinavir or efavirenz concentration parameter was identified as a predictor. Multiple stepwise logistic regressions confirmed the significance of the IQ parameters, as well as other baseline characteristics, in predicting virologic response at 24 weeks in this patient population.

This article has been cited by other articles:

• Robbins, B. L., Capparelli, E. V., Chadwick, E. G., Yogev, R., Serchuck, L., Worrell, C., Smith, M. E., Alvero, C., Fenton, T., Heckman, B., Pelton, S. I., Aldrovandi, G., Borkowsky, W., Rodman, J., Havens, P. L., for the PACTG 1038 Team, (2008). Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors. Antimicrob. Agents Chemother. 52: 3276-3283 [Abstract] [Full Text]  
• Prot, M., Heripret, L., Cardot-Leccia, N., Perrin, C., Aouadi, M., Lavrut, T., Garraffo, R., Dellamonica, P., Durant, J., Le Marchand-Brustel, Y., Binetruy, B. (2006). Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice. Antimicrob. Agents Chemother. 50: 3998-4004 [Abstract] [Full Text]  
• Rosso, R., Di Biagio, A., Dentone, C., Gattinara, G. C., Martino, A. M., Vigano, A., Merlo, M., Giaquinto, C., Rampon, O., Bassetti, M., Gatti, G., Viscoli, C. (2006). Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother 57: 1168-1171 [Abstract] [Full Text]  
• Peng, J. Z., Pulido, F., Causemaker, S. J. K., Li, J., Lorenzo, A., Cepeda, C., Cabanillas, J. A. G., DaSilva, B., Brun, S. C., Arribas, J. (2006). Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus-Coinfected Subjects With Hepatic Impairment.. J Clin Pharmacol 46: 265-274 [Abstract] [Full Text]  
• Andrews, K. T., Fairlie, D. P., Madala, P. K., Ray, J., Wyatt, D. M., Hilton, P. M., Melville, L. A., Beattie, L., Gardiner, D. L., Reid, R. C., Stoermer, M. J., Skinner-Adams, T., Berry, C., McCarthy, J. S. (2006). Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria. Antimicrob. Agents Chemother. 50: 639-648 [Abstract] [Full Text]  
• Marcelin, A.-G., Cohen-Codar, I., King, M. S., Colson, P., Guillevic, E., Descamps, D., Lamotte, C., Schneider, V., Ritter, J., Segondy, M., Peigue-Lafeuille, H., Morand-Joubert, L., Schmuck, A., Ruffault, A., Palmer, P., Chaix, M.-L., Mackiewicz, V., Brodard, V., Izopet, J., Cottalorda, J., Kohli, E., Chauvin, J.-P., Kempf, D. J., Peytavin, G., Calvez, V. (2005). Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 49: 1720-1726 [Abstract] [Full Text]  
• Mo, H., King, M. S., King, K., Molla, A., Brun, S., Kempf, D. J. (2005). Selection of Resistance in Protease Inhibitor-Experienced, Human Immunodeficiency Virus Type 1-Infected Subjects Failing Lopinavir- and Ritonavir-Based Therapy: Mutation Patterns and Baseline Correlates. J. Virol. 79: 3329-3338 [Abstract] [Full Text]  
• Hickman, D., Vasavanonda, S., Nequist, G., Colletti, L., Kati, W. M., Bertz, R., Hsu, A., Kempf, D. J. (2004). Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. Antimicrob. Agents Chemother. 48: 2911-2917 [Abstract] [Full Text]  
• Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Schooley, R. T., Thompson, M. A., Vella, S., Volberding, P. A. (2004). Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel. JAMA 292: 251-265 [Abstract] [Full Text]